Camurus Ab (CAMRF) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Camurus Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.786 -- 00:00:04.810 Thank you so much, Einar, and good day, everyone. 00:00:04.810 -- 00:00:09.055 Thank you for joining our first quarter earnings call. 00:00:09.055 -- 00:00:13.918 As previously, please note our forward-looking statements. 00:00:14.381 -- 00:00:17.745 So the agenda for today's call is as follows. 00:00:17.745 -- 00:00:22.971 We start with business highlights, followed by reviews of financial and commercial 00:00:22.971 -- 00:00:24.573 performance, 00:00:24.573 -- 00:00:29.663 then finish off with a short R&D update before moving over to Q&A. 00:00:29.663 -- 00:00:34.469 So as previously with me today are John Garay, our Chief Financial Officer, and Richard 00:00:34.469 -- 00:00:37.950 Jameson, Chief Commercial Officer. 00:00:38.633 -- 00:00:45.179 So overall, Canberra's had a productive and highly profitable first quarter 2025. 00:00:45.381 -- 00:00:51.048 This was driven by continuous commercial execution in Europe and Australia, strengthening 00:00:51.048 -- 00:00:55.290 our leadership position in opioid dependence treatment, 00:00:55.381 -- 00:01:00.767 Bividual sales increased to 485 million SEK, increasing 6% 00:01:00.767 -- 00:01:05.192 versus the previous year at constant exchange rate. 00:01:05.192 -- 00:01:10.217 Brixari royalties from the US increased 185% versus previous year, however, 00:01:10.217 -- 00:01:15.180 were flat versus previous quarter at CET. 00:01:15.683 -- 00:01:20.869 Notably, the overall buprenorphine OUD market in the US was down 13% 00:01:20.869 -- 00:01:23.410 during the same period. 00:01:23.410 -- 00:01:28.776 In the R&D pipeline, dosing was initiated in a phase one study of R1's monthly 00:01:28.776 -- 00:01:30.699 semaglutide. 00:01:30.699 -- 00:01:35.725 The phase three Sorrento-Positano studies o...